Flyer

Archives of Medicine

  • ISSN: 1989-5216
  • Journal h-index: 11
  • Journal CiteScore: 2.12
  • Journal Impact Factor: 1.0
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
Share This Page

Perspective - (2022) Volume 14, Issue 6

An observation on the effect of baicalin on inflammatory mediator levels

Mohammed Arif*
 
Department of Microbiology, Suleyman Demirel University, Isparta, Turkey
 
*Correspondence: Mohammed Arif, Department of Microbiology, Suleyman Demirel University, Isparta, Turkey, Email:

Received: 28-May-2022, Manuscript No. ipaom-22-12950; Editor assigned: 28-May-2022, Pre QC No. P-12950; Reviewed: 17-Jun-2022, QC No. Q-12950; Revised: 22-Jun-2022, Manuscript No. R-12950; Published: 30-Jun-2022

Abstract

The number of medications currently on the market is incalculable, and their prescription is steadily increasing, raising the risk of severe effects. Currently, the entire population is exposed to a variety of pharmacologic substances, the majority of which are toxic and used without scientific explanation. Even more pharmaceuticals are consumed without medical supervision or prescription, unintentionally, with food, herbal remedies, and over-the-counter medications. This result in widespread toxicity that is difficult to detect, frequently goes unnoticed, and can be highly harmful.

Keywords

Communicable disease; Mouth; Nose; Eyes

Introduction

Because most medications are eliminated through the kidney, it's fair to believe that the kidney could be a special target for their hazardous effects. If you have chronic kidney disease (CKD) diabetes or high blood pressure, or if you use certain blood pressure medications that impact your kidneys, you should take precautions to preserve your kidneys. ACE inhibitors and ARBs are two types of blood pressure medications that can help delay renal failure by slowing the loss of kidney function. If you're taking one of these medications, you can know by its generic name. ACE inhibitors have generic names that end in-pril, while ARBs have generic names that end in – sartan, such as lisinopril and losartan. To achieve your blood pressure targets you may also take a diuretic, generally known as a water pill.

Chronic kidney disease (CKD) is a global health problem that has reached epidemic proportions. For many years, CKD may go undetected. Cardiovascular disease is more common in patients with CKD. Microalbuminuria and lowered GFR are well-known cardiovascular risk factors in both diabetic and no diabetic hypertensive people, and many older patients develop or die from cardiovascular disease rather than ESRD. The findings of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed that chlorthalidone was superior to other medicines in preventing one or more major kinds of cardiovascular disease; however no meaningful difference in all-cause mortality was discovered. In the Prevention of Renal and Vascular End-stage Disease (PREVEND) trial, proteinuria, comprising both micro albuminuria and clinical proteinuria, was identified as a major predictor of kidney disease progression. Through pro-inflammatory and profibro genetic damage in tubular cells, which can facilitate the development of interstitial fibrosis and tubular atrophy and definitely has a pathogenic effect in the loss of renal function.The main study is the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET44), which looked at the effect of telmisartan plus ramipril versus monotherapies in 25,620 patients with established atherosclerotic vascular disease or diabetes with end-organ damage and found a reduction in albuminuria in both the telmisartan (P=0.004) and combination therapy groups (P=0.001) that (median 56 months).When a physician notices a change in renal function, he should take a thorough drug history to see if any of the medications being used could be the cause of the renal impairment. PCr and electrolyte concentrations must be determined, as well as their changes over time. Urinalysis, as well as other tests such as acid– base status, enzymuria, renal echography, urine cultures, eosinophiluria, and eosinophil blood count, should always be done.The most research has probably been done on ACEIs and ARBs. They are the most commonly used drugs in CKD patients, particularly those with diabetes, because of their ability to induce dilation of efferent arterioles in the renal glomerulus, resulting in lower intra-glomerular pressure, and to inhibit pro-inflammatory and proliferative actions of angiotensin II. They also have neutral metabolic effects and have been shown to significantly reduce proteinuria. The long-term effects of other medicines on CKD are less well-studied. CCBs have been shown to efficiently manage blood pressure, -blockers have been shown to regulate sympathetic nervous system over activity seen in chronic renal failure, and diuretics have been shown to limit intravascular volume expansion induced by fluid retention [1-5].

About the Study

Chronic kidney disease (CKD) is a global health problem that has reached epidemic proportions. For many years, CKD may go undetected. Cardiovascular disease is more common in patients with CKD. Microalbuminuria and lowered GFR are well-known cardiovascular risk factors in both diabetic and nondiabetic hypertensive people, and many older patients develop or die from cardiovascular disease rather than ESRD. The findings of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) showed that chlorthalidone was superior to other medicines in preventing one or more major kinds of cardiovascular disease; however no meaningful difference in allcause mortality was discovered

Conclusion

A major threat to global health is posed by illnesses caused by these infections. Subgroups of 3 hours, 6 hours, and 12 hours each were created from these groups (15 rats in each subgroup). Rats were sacrificed 3, 6, and 12 hours following surgery to conduct the experiments described below. The mortality rates of the rats, ascites volume, and pancreatic pathological changes in each group were examined. Amylase, PLA2, TXB2, PGE2, PAF, and IL-1 [beta] concentrations in the blood as well as changes in blood viscosity were also determined.

Conflicts of Interest

The authors declare no competing interests.

All authors declare that the material has not been published elsewhere, or has not been submitted to another publisher.

Data Availability

Authors declare that all related data are available concerning researchers by the corresponding author's email.

Acknowledgments

The views presented in this paper are of the authors and not of the organizations they represent.

References

  1. Naidich JB, Rackson ME, Mossey RT, et al. Nondilated obstructive uropathy: Percutaneous nephrostomy performed to reverse renal failure. Radiol. 1986;160:653-657.
  2. Google Scholar, Crossref, Indexed at

  3. Spital A, Valvo JR, Segal AJ. Nondilated obstructive uropathy. Urol. 1988;3:478-482.
  4. Google Scholar, Crossref, Indexed at

  5. Lameire N, Van Biesen W, Vanholder R. Acute renal failure. Lancet. 2005;365:417-430.
  6. Google Scholar, Crossref, Indexed at

  7. Lyons K, Matthews P, Evans C. Obstructive uropathy without dilatation: A potential diagnostic pitfall. Br Med J. 1988;296:1517-1518.
  8. Google Scholar, Crossref, Indexed at

  9. Onuigbo MAC. Symptomatic uremia from bilateral obstructive uropathy secondary to metastatic urinary bladder cancer showing only unilateral hydronephrosis: A case report. NDT Plus. 2009;2:387-389.
  10. Google Scholar, Crossref, Indexed at